Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Lymphoma

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44339   clinical trials with a EudraCT protocol, of which   7369   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    1,346 result(s) found for: Lymphoma. Displaying page 6 of 68.
    «« First « Previous 2  3  4  5  6  7  8  9  10  Next» Last»»
    EudraCT Number: 2008-004759-31 Sponsor Protocol Number: PACIFICO Start Date*: 2009-06-19
    Sponsor Name:University of Liverpool (lead sponsor, the trial is co−sponsored) [...]
    1. University of Liverpool (lead sponsor, the trial is co−sponsored)
    2. Royal Liverpool and Broadgreen University Hospital NHS Trust
    3.
    Full Title: Purine-Alkylator Combination In Follicular lymphoma Immuno-Chemotherapy for Older patients: a phase III comparison of first-line R-CVP versus R-FC lite
    Medical condition: Follicular Lymphoma in patients aged 60 or over or less than 60 but considered unfit for more aggressive treatment.
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025311 Lymphoma (non-Hodgkin's) LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2017-004628-31 Sponsor Protocol Number: FIL_V-RBAC Start Date*: 2018-05-15
    Sponsor Name:Fondazione Italiana Linfomi ONLUS
    Full Title: Rituximab, bendamustine and cytarabine followed by venetoclax (V-RBAC) in high-risk elderly patients with mantle cell lymphoma (MCL)
    Medical condition: Mantle Cell Lymphoma in elderly patients
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10026799 Mantle cell lymphoma NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-003397-32 Sponsor Protocol Number: MK2140-004 Start Date*: 2021-12-21
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A Phase 2 Open-label Clinical Study to Evaluate the Efficacy and Safety of Zilovertamab Vedotin (MK-2140) in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
    Medical condition: Treatment of participants with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10012818 Diffuse large B-cell lymphoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) ES (Ongoing) IT (Trial now transitioned) PL (Trial now transitioned) NO (Trial now transitioned) EE (Trial now transitioned) CZ (Trial now transitioned) GR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2019-002752-16 Sponsor Protocol Number: GCT3009-01 Start Date*: 2020-11-17
    Sponsor Name:Genmab Holding B.V.
    Full Title: Safety and Efficacy of GEN3009 (DuoHexaBody®-CD37) in Relapsed or Refractory B-cell Non-Hodgkin Lymphoma – A First-in-Human, Open-label, Phase I/IIa Dose Escalation Trial with Dose Expansion Cohorts
    Medical condition: Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (NHL)
    Disease: Version SOC Term Classification Code Term Level
    22.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029547 Non-Hodgkin's lymphoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Prematurely Ended) ES (Prematurely Ended) NL (Completed) FR (Prematurely Ended) BE (Completed)
    Trial results: View results
    EudraCT Number: 2020-002736-73 Sponsor Protocol Number: APG2575CU101 Start Date*: 2021-03-10
    Sponsor Name:Ascentage Pharma Group Inc.
    Full Title: A Phase Ib/II Study of APG-2575 as a Single Agent or in Combination with Other Therapeutic Agents in Patients with Relapsed and/or Refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Ly...
    Medical condition: Relapsed and/or Refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL).
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10009310 CLL LLT
    21.1 100000004864 10003910 B-cell small lymphocytic lymphoma NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Trial now transitioned) PL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2016-000286-23 Sponsor Protocol Number: MS200662_0001 Start Date*: 2016-04-27
    Sponsor Name:Telios Pharma, Inc.
    Full Title: Phase I/II, First in Human, Dose Escalation Trial of TL-895 in Subjects with Relapsed/Refractory B-Cell Malignancies and Expansion in Subjects with Relapsed/Refractory Chronic Lymphocytic Leukemia ...
    Medical condition: B Cell Malignancies and Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004851 10003900 B-cell lymphomas NEC HLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10008976 Chronic lymphocytic leukemia LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10003908 B-cell small lymphocytic lymphoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) HU (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2019-000111-84 Sponsor Protocol Number: ACE-LY-003 Start Date*: 2020-02-04
    Sponsor Name:ACERTA PHARMA BV
    Full Title: An Open-label, Phase 1b/2 Study of Acalabrutinib Alone or in Combination Therapy in Subjects with B-cell Non-Hodgkin Lymphoma
    Medical condition: B-cell Non-Hodgkin Lymphoma
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10067070 Follicular B-cell non-Hodgkin's lymphoma LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10076596 Marginal zone lymphoma PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10012818 Diffuse large B-cell lymphoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2015-004729-15 Sponsor Protocol Number: IPI-145-21 Start Date*: 2016-05-27
    Sponsor Name:Infinity Pharmaceuticals, Inc.
    Full Title: A Phase 2, Randomized Study of Duvelisib Administered in Combination with Rituximab vs R-CHOP in Subjects with Relapsed/Refractory Follicular Lymphoma
    Medical condition: Relapsed/Refractory Follicular Lymphoma
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004864 10029473 Nodular (follicular) lymphoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Prematurely Ended) ES (Completed) IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2007-000219-27 Sponsor Protocol Number: 3129K4-3301-WW Start Date*: 2008-04-25
    Sponsor Name:Wyeth Pharmaceuticals Inc. acting through its division Wyeth Research, a Pfizer Company
    Full Title: An Open-Label, Randomized, Phase 3 Study of Inotuzumab Ozogamicin (CMC-544) Administered in Combination With Rituximab Compared to a Defined Investigator’s Choice Therapy in Subjects With Relapsed ...
    Medical condition: Relapsed or refractory, CD22-Positive, follicular B-cell Non Hodgkin's Lymphoma
    Disease: Version SOC Term Classification Code Term Level
    9.1 10029473 Nodular (follicular) lymphoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) ES (Completed) PT (Prematurely Ended) DE (Completed) FR (Completed) GB (Completed) IE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2020-002686-33 Sponsor Protocol Number: SGN35-031 Start Date*: 2020-12-23
    Sponsor Name:Seattle Genetics, Inc.
    Full Title: A Randomized, Double-blind, Placebo-Controlled, Active Comparator, Multicenter, Phase 3 Study of Brentuximab Vedotin or Placebo in Combination With Lenalidomide and Rituximab in Subjects with Relap...
    Medical condition: diffuse large B-cell lymphoma (DLBCL)
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10012822 Diffuse large B-cell lymphoma refractory PT
    20.0 100000004851 10012819 Diffuse large B-cell lymphomas HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) NL (Prematurely Ended) DK (Trial now transitioned) DE (Completed) CZ (Trial now transitioned) PL (Trial now transitioned) ES (Ongoing) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2014-002117-28 Sponsor Protocol Number: ACE-LY-004 Start Date*: 2015-05-06
    Sponsor Name:Acerta Pharma B.V.
    Full Title: An Open-label, Phase 2 Study of ACP-196 in Subjects with Mantle Cell Lymphoma
    Medical condition: Mantle Cell Lymphoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004851 10026798 Mantle cell lymphomas HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) NL (Completed) BE (Completed) CZ (Completed) ES (Ongoing) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-005552-33 Sponsor Protocol Number: APO3585g Start Date*: 2007-06-06
    Sponsor Name:Genentech Inc.
    Full Title: A PHASE Ib/II, OPEN-LABEL, MULTICENTER STUDY OF THE SAFETY, PHARMACOKINETICS, AND EFFICACY OF Apo2L/TRAIL ADMINISTERED INTRAVENOUSLY IN COMBINATION WITH RITUXIMAB TO SUBJECTS WITH FOLLICULAR AND OT...
    Medical condition: Follicular, CD20+, B-cell non-Hodgkin’s lymphoma.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10029547 Non-Hodgkin's lymphoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) CZ (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-003999-40 Sponsor Protocol Number: EONHL1-20 Start Date*: 2021-02-09
    Sponsor Name:Enterome
    Full Title: A global multicenter phase 1/2 trial of EO2463, a novel microbial-derived peptide therapeutic vaccine, as monotherapy, and in combination with lenalidomide and rituximab, for treatment of patients ...
    Medical condition: Indolent Non-Hodgkin's Lymphoma (Follicular Lymphoma; Marginal Zone Lymphoma)
    Disease: Version SOC Term Classification Code Term Level
    22.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029547 Non-Hodgkin's lymphoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2016-002293-12 Sponsor Protocol Number: PCYC-1142-CA Start Date*: 2017-03-06
    Sponsor Name:Pharmacyclics LLC
    Full Title: Phase 2 study of the combination of ibrutinib plus venetoclax in subjects with treatment-naïve chronic lymphocytic leukemia / small lymphocytic lymphoma
    Medical condition: Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL)
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004864 10008976 Chronic lymphocytic leukemia LLT
    19.0 100000004851 10003909 B-cell small lymphocytic lymphomas HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2005-001500-39 Sponsor Protocol Number: LM01 Start Date*: 2005-09-06
    Sponsor Name:G.I.S.L. - GRUPPO ITALIANO STUDIO LINFOMI
    Full Title: A phase II GISL study of R-HyperCVAD in the treatment of patients with Mantle cell Lymphoma
    Medical condition: treatment of patients with Mantle cell Lymphoma with tha combination R-HyperCVAD
    Disease: Version SOC Term Classification Code Term Level
    9.1 10061275 Mantle cell lymphoma LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-005217-38 Sponsor Protocol Number: DSHNHL2004-2 Start Date*: 2008-07-25
    Sponsor Name:German High Grade Non-Hodgkins Lymphoma group
    Full Title: Randomiseret forsøg der sammenligner 4 og 6 kemoterapicykler med CHOP (Cyklofosfamid, Doxorubicin, Vincristin og Prednison) i 21-dages intervaller, begge med 6 cykler immunterapi med monoklonalt an...
    Medical condition: Patients with untreated aggressive CD20+ Non-Hodgkin’s Lymphoma aged 18 to 60 years without major accompanying disorders with no risk factor according to IPI and no bulky disease (<7,5cm)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10003899 B-cell lymphoma PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DK (Completed) IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-004688-19 Sponsor Protocol Number: MOR208C203 Start Date*: 2015-10-02
    Sponsor Name:MorphoSys AG
    Full Title: A Phase II, Single-Arm, Open-Label, Multicentre Study to Evaluate the Safety and Efficacy of Lenalidomide Combined with MOR00208 in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphom...
    Medical condition: Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R-R DLBCL)
    Disease: Version SOC Term Classification Code Term Level
    18.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10012818 Diffuse large B-cell lymphoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed) CZ (Completed) HU (Completed) DE (Completed) ES (Ongoing) FR (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2019-004474-26 Sponsor Protocol Number: FIL_PREVID Start Date*: 2020-08-12
    Sponsor Name:FONDAZIONE ITALIANA LINFOMI ONLUS
    Full Title: Prephase treatment with prednisone +/- Vitamin D supplementation followed by immunochemotherapy in Elderly patients with Diffuse Large B-Cell Lymphoma (DLBCL). A randomized, open label, phase III s...
    Medical condition: Elderly patients with Diffuse Large B-Cell Lymphoma (DLBCL)
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10012818 Diffuse large B-cell lymphoma PT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2015-004741-54 Sponsor Protocol Number: SGN35-017 Start Date*: 2016-04-05
    Sponsor Name:Seattle Genetics, Inc.
    Full Title: A phase 2 study of brentuximab vedotin in combination with standard of care treatment (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone [RCHOP]) or RCHP (rituximab, cyclophosph...
    Medical condition: Diffuse large B-cell lymphoma (DLBCL)
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004864 10012820 Diffuse large B-cell lymphoma NOS LLT
    19.0 100000004864 10067070 Follicular B-cell non-Hodgkin's lymphoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2005-003479-19 Sponsor Protocol Number: UCL/05/134 Start Date*: 2006-02-02
    Sponsor Name:University College London
    Full Title: A Phase II Single Arm Study of the use of CODOX-M/IVAC with Rituximab (R-CODOX-M/IVAC) in the treatment of patients with Diffuse Large B-Cell Lymphoma (DLBCL) or Burkitt's Lymphoma (BL) of Internat...
    Medical condition: Diffuse large B-cell lymphoma Burkitt's lymphoma
    Disease: Version SOC Term Classification Code Term Level
    13.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006595 Burkitt's lymphoma PT
    13.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10012818 Diffuse large B-cell lymphoma PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 2  3  4  5  6  7  8  9  10  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu May 29 23:04:00 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA